FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954381194> ?p ?o ?g. }

• W2954381194 endingPage "2959" @default.
• W2954381194 startingPage "2949" @default.
• W2954381194 abstract "Objective To investigate the prognostic impact of red blood cell (RBC) transfusion on the outcome after transfemoral transcatheter aortic valve replacement (TAVR). Design Nationwide, retrospective multicenter study. Setting Five University Hospitals. Participants The nationwide FinnValve registry included data from 2,130 patients who underwent TAVR for aortic stenosis from 2008 to 2017. After excluding patients who underwent TAVR through nontransfemoral accesses, 1,818 patients were selected for this analysis. Intervention TAVR with or without coronary revascularization. Measurements and Main Results RBCs were transfused in 293 patients (16.1%). Time-trend analysis showed that the rates of RBC transfusion decreased significantly from 27.5% in 2012 to 10.0% in 2017 (p < 0.0001). Among 281 propensity score matched pairs, RBC transfusion was associated with higher 30-day mortality (7.1% v 0%, p < 0.0001), late mortality (at 5-year, 59.1% v 43.3%, p = 0.008), as well as increased risk of acute kidney injury (17.0% v 4.4%, p < 0.0001), renal replacement therapy (3.6% v 0.4, p < 0.0001) and prolonged hospital stay (mean, 8.5 v 4.7 days, p < 0.0001) compared with patients who did not receive blood transfusion. In the overall series, the risk of adverse events increased significantly with the increasing amount of transfused RBC units and when operation for excessive bleeding was necessary. Consistently with these findings, postoperative hemoglobin drop and nadir level were associated with higher early and late mortality. Conclusions Patients who received blood transfusion after TAVR had an increased risk of early and late adverse events. These adverse effects were particularly evident with increasing amount of RBC transfusion and operations for excessive bleeding. To investigate the prognostic impact of red blood cell (RBC) transfusion on the outcome after transfemoral transcatheter aortic valve replacement (TAVR). Nationwide, retrospective multicenter study. Five University Hospitals. The nationwide FinnValve registry included data from 2,130 patients who underwent TAVR for aortic stenosis from 2008 to 2017. After excluding patients who underwent TAVR through nontransfemoral accesses, 1,818 patients were selected for this analysis. TAVR with or without coronary revascularization. RBCs were transfused in 293 patients (16.1%). Time-trend analysis showed that the rates of RBC transfusion decreased significantly from 27.5% in 2012 to 10.0% in 2017 (p < 0.0001). Among 281 propensity score matched pairs, RBC transfusion was associated with higher 30-day mortality (7.1% v 0%, p < 0.0001), late mortality (at 5-year, 59.1% v 43.3%, p = 0.008), as well as increased risk of acute kidney injury (17.0% v 4.4%, p < 0.0001), renal replacement therapy (3.6% v 0.4, p < 0.0001) and prolonged hospital stay (mean, 8.5 v 4.7 days, p < 0.0001) compared with patients who did not receive blood transfusion. In the overall series, the risk of adverse events increased significantly with the increasing amount of transfused RBC units and when operation for excessive bleeding was necessary. Consistently with these findings, postoperative hemoglobin drop and nadir level were associated with higher early and late mortality. Patients who received blood transfusion after TAVR had an increased risk of early and late adverse events. These adverse effects were particularly evident with increasing amount of RBC transfusion and operations for excessive bleeding." @default.
• W2954381194 created "2019-07-12" @default.
• W2954381194 creator A5010870573 @default.
• W2954381194 creator A5013370073 @default.
• W2954381194 creator A5013455952 @default.
• W2954381194 creator A5014280780 @default.
• W2954381194 creator A5019715232 @default.
• W2954381194 creator A5021723997 @default.
• W2954381194 creator A5028512167 @default.
• W2954381194 creator A5028936923 @default.
• W2954381194 creator A5031486545 @default.
• W2954381194 creator A5031785884 @default.
• W2954381194 creator A5033796392 @default.
• W2954381194 creator A5053429712 @default.
• W2954381194 creator A5053777533 @default.
• W2954381194 creator A5055770780 @default.
• W2954381194 creator A5060570812 @default.
• W2954381194 creator A5065916561 @default.
• W2954381194 creator A5066640503 @default.
• W2954381194 creator A5071638295 @default.
• W2954381194 creator A5076242520 @default.
• W2954381194 creator A5077406821 @default.
• W2954381194 creator A5077451968 @default.
• W2954381194 creator A5080965346 @default.
• W2954381194 creator A5084986778 @default.
• W2954381194 creator A5088039325 @default.
• W2954381194 date "2019-11-01" @default.
• W2954381194 modified "2023-10-16" @default.
• W2954381194 title "Blood Transfusion and Outcome After Transfemoral Transcatheter Aortic Valve Replacement" @default.
• W2954381194 cites W1702536112 @default.
• W2954381194 cites W1797068298 @default.
• W2954381194 cites W1847395304 @default.
• W2954381194 cites W1992447975 @default.
• W2954381194 cites W2013204694 @default.
• W2954381194 cites W2039349506 @default.
• W2954381194 cites W2109802639 @default.
• W2954381194 cites W2148793684 @default.
• W2954381194 cites W2273742554 @default.
• W2954381194 cites W2554509737 @default.
• W2954381194 cites W2579169727 @default.
• W2954381194 cites W2746458656 @default.
• W2954381194 cites W2748402856 @default.
• W2954381194 cites W2767670516 @default.
• W2954381194 cites W2781758742 @default.
• W2954381194 cites W2890959687 @default.
• W2954381194 cites W2895865500 @default.
• W2954381194 cites W2896071904 @default.
• W2954381194 cites W2899778315 @default.
• W2954381194 cites W2903840886 @default.
• W2954381194 cites W2914461374 @default.
• W2954381194 cites W2920762375 @default.
• W2954381194 cites W2944995402 @default.
• W2954381194 cites W4239001479 @default.
• W2954381194 cites W4293496224 @default.
• W2954381194 doi "https://doi.org/10.1053/j.jvca.2019.06.038" @default.
• W2954381194 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31350150" @default.
• W2954381194 hasPublicationYear "2019" @default.
• W2954381194 type Work @default.
• W2954381194 sameAs 2954381194 @default.
• W2954381194 citedByCount "12" @default.
• W2954381194 countsByYear W29543811942019 @default.
• W2954381194 countsByYear W29543811942020 @default.
• W2954381194 countsByYear W29543811942021 @default.
• W2954381194 countsByYear W29543811942022 @default.
• W2954381194 countsByYear W29543811942023 @default.
• W2954381194 crossrefType "journal-article" @default.
• W2954381194 hasAuthorship W2954381194A5010870573 @default.
• W2954381194 hasAuthorship W2954381194A5013370073 @default.
• W2954381194 hasAuthorship W2954381194A5013455952 @default.
• W2954381194 hasAuthorship W2954381194A5014280780 @default.
• W2954381194 hasAuthorship W2954381194A5019715232 @default.
• W2954381194 hasAuthorship W2954381194A5021723997 @default.
• W2954381194 hasAuthorship W2954381194A5028512167 @default.
• W2954381194 hasAuthorship W2954381194A5028936923 @default.
• W2954381194 hasAuthorship W2954381194A5031486545 @default.
• W2954381194 hasAuthorship W2954381194A5031785884 @default.
• W2954381194 hasAuthorship W2954381194A5033796392 @default.
• W2954381194 hasAuthorship W2954381194A5053429712 @default.
• W2954381194 hasAuthorship W2954381194A5053777533 @default.
• W2954381194 hasAuthorship W2954381194A5055770780 @default.
• W2954381194 hasAuthorship W2954381194A5060570812 @default.
• W2954381194 hasAuthorship W2954381194A5065916561 @default.
• W2954381194 hasAuthorship W2954381194A5066640503 @default.
• W2954381194 hasAuthorship W2954381194A5071638295 @default.
• W2954381194 hasAuthorship W2954381194A5076242520 @default.
• W2954381194 hasAuthorship W2954381194A5077406821 @default.
• W2954381194 hasAuthorship W2954381194A5077451968 @default.
• W2954381194 hasAuthorship W2954381194A5080965346 @default.
• W2954381194 hasAuthorship W2954381194A5084986778 @default.
• W2954381194 hasAuthorship W2954381194A5088039325 @default.
• W2954381194 hasBestOaLocation W29543811942 @default.
• W2954381194 hasConcept C126322002 @default.
• W2954381194 hasConcept C141071460 @default.
• W2954381194 hasConcept C164705383 @default.
• W2954381194 hasConcept C167135981 @default.
• W2954381194 hasConcept C2776570981 @default.
• W2954381194 hasConcept C2777396833 @default.
• W2954381194 hasConcept C2779464278 @default.

• next